Prognostic value of CT findings to predict survival outcomes in patients with pancreatic neuroendocrine neoplasms: a single institutional study of 161 patients

被引:31
|
作者
Kim, Dong Wook [1 ,2 ]
Kim, Hyoung Jung [1 ,2 ]
Kim, Kyung Won [1 ,2 ]
Byun, Jae Ho [1 ,2 ]
Kim, So Yeon [1 ,2 ]
Song, Ki Byung [3 ]
Ramaiya, Nikhil H. [4 ]
Tirumani, Sree Harsha [4 ]
Hong, Seung-Mo [5 ]
机构
[1] Univ Ulsan, Coll Med, Dept Radiol, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[2] Univ Ulsan, Coll Med, Res Inst Radiol, Asan Med Ctr, 86 Asanbyeongwon Gil, Seoul 138736, South Korea
[3] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Surg, Seoul 138736, South Korea
[4] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging,Brigham & Womens Hosp, 44 Binney St, Boston, MA 02115 USA
[5] Univ Ulsan, Coll Med, Asan Med Ctr, Dept Pathol, Seoul 138736, South Korea
关键词
Pancreas; Neuroendocrine neoplasm; Overall survival; Recurrence free survival; CT; ENDOCRINE TUMORS; MICROVASCULAR DENSITY; HELICAL CT; ADENOCARCINOMA; CLASSIFICATION; EXPRESSION; FEATURES; SYSTEM; CANCER; MDCT;
D O I
10.1007/s00330-015-3943-5
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To evaluate the prognostic value of CT to predict recurrence-free and overall survival in patients with pancreatic neuroendocrine neoplasms (PanNENs). Methods Between January 2004 and December 2012, 161 consecutive patients who underwent preoperative triphasic CT and surgical resection with curative intent for PanNENs were identified. The tumour consistency, margin, presence of calcification, pancreatic duct dilatation, bile duct dilatation, vascular invasion, and hepatic metastases were evaluated. The tumour size, arterial enhancement ratio, and portal enhancement ratio were measured. The Cox proportional hazard model was used to determine the association between CT features and recurrence-free survival and overall survival. Results By multivariate analysis, tumour size (> 3 cm) (hazard ratio, 3.314; p = 0.006), portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 2.718; p = 0.006), and hepatic metastases (hazard ratio, 4.374; p = 0.003) were independent significant variables for worse recurrence-free survival. Portal enhancement ratio (a parts per thousand currency sign1.1) (hazard ratio, 5.951; p = 0.001) and hepatic metastases (hazard ratio, 4.122; p = 0.021) were independent significant variables for worse overall survival. Conclusions Portal enhancement ratio (a parts per thousand currency sign1.1) and hepatic metastases assessed on CT were common independent prognostic factors for worse recurrence-free survival and overall survival in patients with PanNENs.
引用
收藏
页码:1320 / 1329
页数:10
相关论文
共 50 条
  • [21] Clinicopathological Findings and Treatment Outcomes of Patients with Primary Hepatobiliary Neuroendocrine Neoplasms: A Retrospective Single-institution Analysis
    Komiyama, Satoshi
    Okusaka, Takuji
    Maruki, Yuta
    Ohba, Akihiro
    Nagashio, Yoshikuni
    Kondo, Shunsuke
    Hijioka, Susumu
    Morizane, Chigusa
    Ueno, Hideki
    Sukeda, Aoi
    Mizui, Takahiro
    Takamoto, Takeshi
    Nara, Satoshi
    Ban, Daisuke
    Esaki, Minoru
    Hiraoka, Nobuyoshi
    Shimada, Kazuaki
    INTERNAL MEDICINE, 2024, 63 (07) : 891 - 901
  • [22] Trends in the Incidence and Survival Outcomes in Patients With Lung Neuroendocrine Neoplasms in the United States
    Shah, S.
    Gosain, R.
    Groman, A.
    Gosain, R.
    Dasari, A.
    Halfdanarson, T. R.
    Mukherjee, S.
    PANCREAS, 2021, 50 (03) : 461 - 461
  • [23] Prognostic value of initial chest CT findings for clinical outcomes in patients with COVID-19
    Liu, Song
    Nie, Chen
    Xu, Qizhong
    Xie, Hong
    Wang, Maoren
    Yu, Chengxin
    Hou, Xuewen
    INTERNATIONAL JOURNAL OF MEDICAL SCIENCES, 2021, 18 (01): : 270 - 275
  • [24] CT findings predict survival of patients with peripheral T cell lymphoma: a preliminary study
    Yang, Wenbin
    Jiang, Sen
    Lin, Jianbang
    Li, Yangkang
    RADIOLOGY AND ONCOLOGY, 2019, 53 (01) : 31 - 38
  • [25] Incidence and survival of patients with malignant pancreatic neuroendocrine neoplasms in Germany, 2009-2021
    Stang, Andreas
    Wellmann, Ina
    Holleczek, Bernd
    Kim-Wanner, Soo-Zin
    Mueller-Nordhorn, Jacqueline
    Sirri, Eunice
    Wittenberg, Ian
    Siveke, Jens T.
    Kajueter, Hiltraud
    CANCER EPIDEMIOLOGY, 2024, 93
  • [26] Pre-operative dysglycemia is associated with decreased survival in patients with pancreatic neuroendocrine neoplasms
    Sandini, Marta
    Strobel, Oliver
    Hank, Thomas
    Lewosinska, Magdalena
    Niessen, Anna
    Hackert, Thilo
    Buechler, Markus W.
    Schimmack, Simon
    SURGERY, 2020, 167 (03) : 575 - 580
  • [27] Surgery after sunitinib administration to improve survival of patients with advanced pancreatic neuroendocrine neoplasms
    Murase, Yoshiki
    Kudo, Atsushi
    Akahoshi, Keiichi
    Maekawa, Aya
    Ishikawa, Yoshiya
    Ueda, Hiroki
    Ogawa, Kosuke
    Ono, Hiroaki
    Tanaka, Shinji
    Tanabe, Minoru
    ANNALS OF GASTROENTEROLOGICAL SURGERY, 2021, 5 (05): : 692 - 700
  • [28] Prognostic models to predict survival in patients with pancreatic cancer: a systematic review
    Ioannou, Liane J.
    Maharaj, Ashika D.
    Zalcberg, John R.
    Loughnan, Jesse T.
    Croagh, Daniel G.
    Pilgrim, Charles H.
    Goldstein, David
    Kench, James G.
    Merrett, Neil D.
    Earnest, Arul
    Burmeister, Elizabeth A.
    White, Kate
    Neale, Rachel E.
    Evans, Sue M.
    HPB, 2022, 24 (08) : 1201 - 1216
  • [29] Clinical Outcomes of Everolimus Rechallenge in Patients with Pancreatic Neuroendocrine Neoplasms with No Other Treatment Options
    Kurita, Yusuke
    Kobayashi, Noritoshi
    Hara, Kazuo
    Mizuno, Nobumasa
    Kuwahara, Takamichi
    Okuno, Nozomi
    Haba, Shin
    Tokuhisa, Motohiko
    Hasegawa, Sho
    Kubota, Kensuke
    Nakajima, Atsushi
    Ichikawa, Yasushi
    CANCERS, 2022, 14 (22)
  • [30] Incidence, survival, and prognostic factors for patients with gastrointestinal mixed neuroendocrine non-neuroendocrine neoplasms: a SEER population-based study
    Xu, Boqi
    Zhang, Fan
    Wu, Runda
    Peng, Yao
    Mao, Zhongqi
    Tong, Shan
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (17) : 15657 - 15669